Novartis Issues Debt Offering to Help Fund $12B Acquisition of Avidity Biosciences

Dow Jones

03/17

By Kelly Cloonan

Novartis is issuing debt offerings to help fund its $12 billion acquisition of Avidity Biosciences.

The Swiss pharmaceutical company plans to use the proceeds from the sale of the notes for general corporate purposes outside of Switzerland, including to repay outstanding borrowings under the bridge loan it entered last month to finance the Avidity acquisition, according to a filing with the Securities and Exchange Commission.

Novartis didn't disclose the size of the debt offering. The offering includes eight tranches, with notes due in 2029, 2031, 2033, 2036, 2046 and 2056 and floating rate notes due in 2029 and 2031.

The company's acquisition of Avidity closed in February, adding to a series of smaller acquisitions and licensing agreements that have allowed Novartis to fill its drug pipeline. Avidity brings two experimental drugs for neuromuscular diseases.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

March 16, 2026 13:29 ET (17:29 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2620498618"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620498618\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620498618?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-17 01:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620498618","market":"fut","top_or_hot":-1,"title":"Novartis Issues Debt Offering to Help Fund $12B Acquisition of Avidity Biosciences","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Novartis is issuing debt offerings to help fund its $12 billion acquisition of <a href=\"https://laohu8.com/S/RNA\">Avidity Biosciences</a>. \n</p>\n<p>\n  The Swiss pharmaceutical company plans to use the proceeds from the sale of the notes for general corporate purposes outside of Switzerland, including to repay outstanding borrowings under the bridge loan it entered last month to finance the Avidity acquisition, according to a filing with the Securities and Exchange Commission. \n</p>\n<p>\n  Novartis didn't disclose the size of the debt offering. The offering includes eight tranches, with notes due in 2029, 2031, 2033, 2036, 2046 and 2056 and floating rate notes due in 2029 and 2031. \n</p>\n<p>\n  The company's acquisition of Avidity closed in February, adding to a series of smaller acquisitions and licensing agreements that have allowed Novartis to fill its drug pipeline. Avidity brings two experimental drugs for neuromuscular diseases. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 16, 2026 13:29 ET (17:29 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis Issues Debt Offering to Help Fund $12B Acquisition of Avidity Biosciences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis Issues Debt Offering to Help Fund $12B Acquisition of Avidity Biosciences\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-03-17 01:29</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Novartis is issuing debt offerings to help fund its $12 billion acquisition of <a href=\"https://laohu8.com/S/RNA\">Avidity Biosciences</a>. \n</p>\n<p>\n  The Swiss pharmaceutical company plans to use the proceeds from the sale of the notes for general corporate purposes outside of Switzerland, including to repay outstanding borrowings under the bridge loan it entered last month to finance the Avidity acquisition, according to a filing with the Securities and Exchange Commission. \n</p>\n<p>\n  Novartis didn't disclose the size of the debt offering. The offering includes eight tranches, with notes due in 2029, 2031, 2033, 2036, 2046 and 2056 and floating rate notes due in 2029 and 2031. \n</p>\n<p>\n  The company's acquisition of Avidity closed in February, adding to a series of smaller acquisitions and licensing agreements that have allowed Novartis to fill its drug pipeline. Avidity brings two experimental drugs for neuromuscular diseases. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 16, 2026 13:29 ET (17:29 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B2B36J28.USD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2620498618","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620498618","pubTimestamp":1773682140,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Novartis is issuing debt offerings to help fund its $12 billion acquisition of Avidity Biosciences.The Swiss pharmaceutical company plans to use the proceeds from the sale of the notes for general corporate purposes outside of Switzerland, including to repay outstanding borrowings under the bridge loan it entered last month to finance the Avidity acquisition, according to a filing with the Securities and Exchange Commission.Novartis didn't disclose the size of the debt offering. The offering includes eight tranches, with notes due in 2029, 2031, 2033, 2036, 2046 and 2056 and floating rate notes due in 2029 and 2031.The company's acquisition of Avidity closed in February, adding to a series of smaller acquisitions and licensing agreements that have allowed Novartis to fill its drug pipeline. Avidity brings two experimental drugs for neuromuscular diseases.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4588":"碎股","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4007":"制药","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","BK4532":"文艺复兴科技持仓","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","NVS":"诺华","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4505":"高瓴资本持仓","BK4578":"CAR-T","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","RNA":"Atrium Therapeutics"},"translate_title":"诺华发行债务为120B美元收购Avidity Biosciences提供资金","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":0.9,"RNA":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Novartis is issuing debt offerings to help fund its $12 billion acquisition of Avidity Biosciences. \n\n\n  The Swiss pharmaceutical company plans to use the proceeds from the sale of the notes for general corporate purposes outside of Switzerland, including to repay outstanding borrowings under the bridge loan it entered last month to finance the Avidity acquisition, according to a filing with the Securities and Exchange Commission. \n\n\n  Novartis didn't disclose the size of the debt offering. The offering includes eight tranches, with notes due in 2029, 2031, 2033, 2036, 2046 and 2056 and floating rate notes due in 2029 and 2031. \n\n\n  The company's acquisition of Avidity closed in February, adding to a series of smaller acquisitions and licensing agreements that have allowed Novartis to fill its drug pipeline. Avidity brings two experimental drugs for neuromuscular diseases. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 16, 2026 13:29 ET (17:29 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}